This publication does not argue against an ambitious agenda for change. On the contrary, Australia's decision-making on health technologies is crying out for change. The argument is that it cannot be delivered within the constraints of an institution that has never demonstrated any ability to reform itself, engage in self-reflection, or take responsibility for the issues afflicting access in Australia.
Be clear-eyed about whatever trade-offs the institution demands you accept
September 10, 2024 Latest NewsBioPharmaCommentLatest Video
New Stories
-
Immutep says its candidate in combination with Keytruda delivered positive efficacy and safety profile
September 16, 2024 - - Latest News -
Medicines Australia responds to questions on the HTA Review
September 16, 2024 - - Latest News -
The HTA Review report - 'Red Flag' number two of five
September 16, 2024 - - Latest News -
Australian company Kazia executes licensing agreement with QIMR Berghofer
September 16, 2024 - - Latest News -
A statement with intent that limits expectations and frames reform as a one-sided trade-off
September 16, 2024 - - Latest News -
The HTA Review report - 'Red Flag' number one of five
September 16, 2024 - - Latest News -
Pharmac announces plan to deploy more of its recent funding boost
September 16, 2024 - - Latest News